NFE2L2 and pulmonary fibrosis: Upregulation of Histone deacetylase 3 (HDAC3) in pulmonary fibrosis can lead to NRF2 inhibition, and by selectively inhibiting HDAC3 (e.g., using the drug RGFP966), the inhibitory effect on NRF2 can be reduced.